260 related articles for article (PubMed ID: 36339340)
1. Features of cytomegalovirus infection and evaluation of cytomegalovirus-specific T cells therapy in children's patients following allogeneic hematopoietic stem cell transplantation: A retrospective single-center study.
Ruan Y; Luo T; Liu Q; Liu X; Chen L; Wen J; Xiao Y; Xie D; He Y; Wu X; Feng X
Front Cell Infect Microbiol; 2022; 12():1027341. PubMed ID: 36339340
[TBL] [Abstract][Full Text] [Related]
2. Patients with refractory cytomegalovirus (CMV) infection following allogeneic haematopoietic stem cell transplantation are at high risk for CMV disease and non-relapse mortality.
Liu J; Kong J; Chang YJ; Chen H; Chen YH; Han W; Wang Y; Yan CH; Wang JZ; Wang FR; Chen Y; Zhang XH; Xu LP; Liu KY; Huang XJ
Clin Microbiol Infect; 2015 Dec; 21(12):1121.e9-15. PubMed ID: 26093077
[TBL] [Abstract][Full Text] [Related]
3. Haploidentical allogeneic hematopoietic stem cell transplantation increases the risk of cytomegalovirus infection in adult patients with acute leukemia.
Lin CH; Su YJ; Hsu CY; Wang PN; Teng CJ
Transpl Infect Dis; 2019 Aug; 21(4):e13096. PubMed ID: 31004545
[TBL] [Abstract][Full Text] [Related]
4. Incidence, features, and outcomes of cytomegalovirus DNAemia in unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with post-transplantation cyclophosphamide.
Huntley D; Giménez E; Pascual MJ; Hernández-Boluda JC; Gago B; Vázquez L; Piñana JL; García M; Pérez A; Serrano D; Hernández M; Albert E; Solano C; Navarro D
Transpl Infect Dis; 2020 Feb; 22(1):e13206. PubMed ID: 31677215
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic letermovir decreases cytomegalovirus reactivation after stem cell transplantation: a single-center real-world evidence study.
Serio B; Giudice V; Guariglia R; Fontana R; Pezzullo L; Martorelli MC; Ferrara I; Mettivier L; D'Addona M; Vaccaro E; Langella M; Selleri C
Infez Med; 2021 Mar; 29(1):102-113. PubMed ID: 33664179
[TBL] [Abstract][Full Text] [Related]
6. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.
Neuenhahn M; Albrecht J; Odendahl M; Schlott F; Dössinger G; Schiemann M; Lakshmipathi S; Martin K; Bunjes D; Harsdorf S; Weissinger EM; Menzel H; Verbeek M; Uharek L; Kröger N; Wagner E; Kobbe G; Schroeder T; Schmitt M; Held G; Herr W; Germeroth L; Bonig H; Tonn T; Einsele H; Busch DH; Grigoleit GU
Leukemia; 2017 Oct; 31(10):2161-2171. PubMed ID: 28090089
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus infection and rehospitalization rates after allogeneic hematopoietic stem cell and solid organ transplantation: a retrospective cohort study using German claims data.
Teschner D; Knop J; Piehl C; Junker S; Witzke O
Infection; 2022 Dec; 50(6):1543-1555. PubMed ID: 35633464
[TBL] [Abstract][Full Text] [Related]
8. Adoptive therapy with cytomegalovirus-specific cytotoxic T lymphocytes for refractory cytomegalovirus DNAemia and disease after allogeneic haematopoietic stem cell transplantation.
Jiang Z; Fan Z; Zhang T; Lin R; Xu H; Xu N; Huang F; Chi P; Ou X; Wang Z; Liu H; Zhao K; Jiang L; Yu S; Sun J; Liu Q; Xuan L
Br J Haematol; 2024 Apr; 204(4):1393-1401. PubMed ID: 38168845
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
10. Different recovery patterns of CMV-specific and WT1-specific T cells in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: Impact of CMV infection and leukemia relapse.
Luo XH; Poiret T; Liu Z; Meng Q; Nagchowdhury A; Ljungman P
Front Immunol; 2022; 13():1027593. PubMed ID: 36824620
[TBL] [Abstract][Full Text] [Related]
11. [Cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and related risk factors].
Huang XJ; Xu LP; Ren HY; Zhang YC; Guo NL; Lu DP
Zhonghua Yi Xue Za Zhi; 2003 May; 83(9):766-9. PubMed ID: 12899755
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of risk factors for secondary cytopenia after allogeneic hematopoietic stem cell transplantation].
Lin Z; Kong Y; Wang Y; Zhang X; Liu D; Xu L; Huang X
Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):4-8. PubMed ID: 24602722
[TBL] [Abstract][Full Text] [Related]
13. [Effect of Plasmacytoid Dendritic Cell Dose in Grafts on CMV Infection after Allogeneic Hematopoietic Stem Cell Transplantation].
Yao D; Tian YY; Lu J; Xiao PF; Ling J; Zheng DF; Gao J; Fan LY; Zheng JJ; Li J; Hu SY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Aug; 31(4):1184-1191. PubMed ID: 37551496
[TBL] [Abstract][Full Text] [Related]
14. Ten-year epidemiology and risk factors of cytomegalovirus infection in hematopoietic stem cell transplantation patients in Taiwan.
Huang YC; Hsiao FY; Guan ST; Yao M; Liu CJ; Chen TT; Lin TL; Liu YC; Chen TY; Hong YC; Ma MC; Tan TD; Wang CC; Wu YY; Liao PW; Wu YF; Chen YY; Yu YB; Hsieh YY; Lee MY; Liu JH; Lin SW; Ko BS
J Microbiol Immunol Infect; 2024 Jun; 57(3):365-374. PubMed ID: 38503632
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus management after allogeneic hematopoietic stem cell transplantation: A mini-review.
Jerry Teng CL; Wang PN; Chen YC; Ko BS
J Microbiol Immunol Infect; 2021 Jun; 54(3):341-348. PubMed ID: 33514495
[TBL] [Abstract][Full Text] [Related]
16. Reconstitution of cytomegalovirus-specific T-cell immunity following unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide.
Huntley D; Giménez E; Pascual MJ; Remigia MJ; Amat P; Vázquez L; Hernández M; Hernández-Boluda JC; Gago B; Piñana JL; García M; Martínez A; Mateo E; Gozalbo-Rovira R; Albert E; Solano C; Navarro D
Bone Marrow Transplant; 2020 Jul; 55(7):1347-1356. PubMed ID: 32205853
[TBL] [Abstract][Full Text] [Related]
17. Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients.
Seo E; Choi ES; Kim JH; Kim H; Koh KN; Im HJ; Lee J
PLoS One; 2021; 16(2):e0246191. PubMed ID: 33544726
[TBL] [Abstract][Full Text] [Related]
18. The clinical and economic impact of cytomegalovirus infection in recipients of hematopoietic stem cell transplantation.
Webb BJ; Harrington R; Schwartz J; Kammerer J; Spalding J; Lee E; Dodds B; Kaufusi S; Goodman BE; Firth SD; Martin G; Sorensen J; Hoda D
Transpl Infect Dis; 2018 Oct; 20(5):e12961. PubMed ID: 29975816
[TBL] [Abstract][Full Text] [Related]
19. Cytomegalovirus reactivation under pre-emptive therapy following allogeneic hematopoietic stem cell transplant: Pattern, survival, and risk factors in the Republic of Korea.
Kang KW; Jeon MJ; Yu ES; Kim DS; Lee BH; Lee SR; Choi CW; Park Y; Kim BS; Sung HJ
PLoS One; 2023; 18(9):e0291268. PubMed ID: 37703263
[TBL] [Abstract][Full Text] [Related]
20. [Application of real time polymerase chain reaction to the diagnosis and treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation].
Chen H; Liu KY; Xu LP; Liu DH; Chen YH; Zhao XS; Yu L; Han W; Zhang XH; Wang Y; Chen Y; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2009 Feb; 30(2):77-81. PubMed ID: 19563015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]